Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma
- PDF / 585,760 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 115 Downloads / 189 Views
ORIGINAL ARTICLE
Evaluation of prognosis following early disease progression in peripheral T‑cell lymphoma Yasuhiro Suzuki1 · Takahiro Yano2 · Youko Suehiro3 · Hiromi Iwasaki4 · Michihiro Hidaka5 · Maki Otsuka6 · Kazutaka Sunami7 · Hirokazu Ikeda8 · Morio Sawamura9 · Takuo Ito10 · Hiroatsu Iida1 · Hirokazu Nagai1,11 Received: 18 February 2020 / Revised: 19 August 2020 / Accepted: 25 August 2020 © Japanese Society of Hematology 2020
Abstract Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated. Keywords Non-Hodgkin lymphoma · Peripheral T-cell lymphoma · Early disease progression · POD24 · Clinical practice
Introduction Peripheral T-cell lymphoma (PTCL) is an aggressive lymphoma that is biologically and clinically heterogeneous and often has poor clinical outcomes [1]. Despite the Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12185-020-02987-7) contains supplementary material, which is available to authorized users.
6
Department of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
7
Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
8
Department of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
Department of Hematology, National Hospital Organization Osaka Medical Center, Osaka, Japan
9
Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan
10
Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
Department of Hematology, National Hospital Organization Kure Medical Center, Kure, Japan
11
Clinical Research Center
Data Loading...
